Meta-analysis of coagulation disbalances in COVID-19: 41 studies and 17601 patients

Polina Len¹ 1 Polina Len¹, Gaukhar Iskakova^{1,#}, Zarina Sautbayeva^{1,#}, Aigul
2 Kussanova^{1,2,#}, Ainur T. Tauekelova³, Madina M. Sugralimova³, Anar S. **Kussanova^{1,2,#}, Ainur T. Tauekelova³, Madina M. Sugralimova³, Anar S.
2. Douthogy**³ Morrort M. Abdieva³ Excess D. Penemanar⁴ Alexander **Dautbaeva³, Meruert M. Abdieva³, Eugene D. Ponomarev⁴, Alexander Titlebangs** Matcheson S. Bortonewa^{1,5,6*} **Tikhonov1 , Makhabbat S. Bekbossynova3,*, Natasha S. Barteneva1,5,6*** ⁴

- ¹ School of Sciences and Humanities, Nazarbayev University, Nur-Sultan, Kazakhstan
- ² Core Facilities, Nazarbayev University, Nur-Sultan, Kazakhstan
- ³National Research Center for Cardiac Surgery, Nur-Sultan, Kazakhstan
- ⁴ School of Biomedical Sciences, Chinese University of Hong Kong, Shatin. Hong Kong
- ⁵ National Laboratory Astana, Nur-Sultan, Kazakhstan
- ⁶ 10Brigham and Women's Hospital, Harvard Medical School, Boston, USA
- [#]These authors made an equal contribution in the study
- 12 *Joint senior authors
13
-
- 14 Keywords: COVID-19; coagulopathy; thrombosis; D-dimers; platelets; fibrinogen: immature
- 15 reticulated platelets; prothrombin time

16

¹⁷**Abstract**

¹⁸**Introduction.** Coagulation parameters are important determinants for COVID-19 infection. ¹⁹We conducted meta-analysis to assess the early hemostatic parameters in retrospective 20 studies in association with severity of infection.

²¹**Methods.** Ovid, PubMed, Web of Sciences, and Google Scholar were searched for research 22 articles that addressed clinical characteristics of COVID-19 patients and disease severity. 23 Results were filtered using exclusion and inclusion criteria and then pooled into a meta-²⁴analysis to estimate the standardized mean difference with 95% CI for each of five 25 coagulation parameters (D-dimers, fibrinogen, prothrombin time, platelets count, activated 26 partial thromboplastin time). Two authors independently extracted data and assessed study 27 quality. To explore the heterogeneity and robustness of our fundings, sensitivity and 28 subgroup analyses were conducted. Publication bias was assessed with contour-enhanced 29 funnel plots and Egger test by linear regression.

Results. Overall, 41 original studies (17601 patients) on SARS-CoV2 were included. For the 31 two groups of patients, stratified by severity, we identified that D-dimers, fibrinogen, 32 activated partial thromboplastin time, and prothrombin time were significantly higher in the severe group (SMD 0.6985 with 95%CI [0.5155; 0.8815]); SMD 0.661with 95%CI [0.3387; 0.9833]; SMD 0.2683 with 95%CI [0.1357; 0.4009]; SMD 0.284 with 95%CI [0.1472; 0.4208]). In contrast, PLT was significantly lower in patients with more severe cases of COVID-19 (SMD -0.1684 with 95%CI [-0.2826; -0.0542]). Neither the analysis by the leave-one-out method nor the influence diagnostic have identified studies that solely cause significant change in the effect size estimates. Subgroup analysis showed no significant 39 difference between articles originated from different countries but revealed that severity assessment criteria might have influence over estimated effect sizes for platelets and D-

⁶⁷**¹ Introduction**

⁶⁸In less than two years of the outbreak, the COVID-19 pandemic took almost five million ⁶⁹lives (John Hopkins, 2021). SARS-CoV-2 is the seventh member of the large coronavirus 70 family capable of inducing human disease (Carsana et al., 2020). Viral respiratory infections, ⁷¹including severe respiratory acute syndrome coronavirus (SARS-CoV), Middle East 72 respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 may induce coagulopathy 73 and lead to intravascular thrombi and deposition of fibrinogen (Hwang et al., 2005; Yang et ⁷⁴al., 2005; Goeijenbier et al., 2012; WHO MERS guidelines, 2013; Giannis et al., 2020).

75 The coagulation system is activated and dysregulated during COVID-19 infection; however, ⁷⁶characteristics of COVID-19 associated coagulopathy are different from coagulation ⁷⁷disorders (Iba et al., 2020). Evidence of abnormal COVID-19-associated coagulation 78 parameters appeared already in early publications from Wuhan (Chen et al., 2020; Wang et ⁷⁹al., 2020; Zhou et al., 2020) and was supported by further publications worldwide (rev. Levi 80 et al., 2020; Iba et al., 2020). The reported hemostatic abnormalities with COVID-19 81 infection include increased D-dimers levels (Lippi et al., 2020; Demelo-Rodriguez et al., ⁸²2020), fibrinogen levels (Ranucci et al., 2020; Panigada et al., 2020), changes in the 83 quantities and levels of activation of platelets (Yang et al., 2020; Lippi et al., 2020; Hottz et ⁸⁴al., 2020; Althaus et al., 2021), elevated von Willebrand factor (Goshua et al., 2020; ⁸⁵Doevelaar et al., 2021, rev. by Becker et al., 2021) and other coagulation parameters. 86 Persistently elevated thrombocytic events, even with initiation of prophylactic anti-87 coagulation, suggest the presence of hypofibrinolysis in addition to detected 88 hypercoagulability in COVID-19 (Creel-Bulos et al., 2021; Bachler et al., 2021). It is also 89 consistent with results of thromboelastography (TEG) reported by Wright et al. (2020).

⁹⁰There is a need in early detection of elevated coagulation biomarkers to optimize risk 91 stratification of patients with COVID-19. However, due to limitations of early pandemic

92 research with small study sizes and highly heterogeneous datasets it is still debated. The aim 93 of the current study was to evaluate the validity of stratification based on early coagulation 94 parameters provided by different clinical studies worldwide. We also aimed to use subgroup 95 analysis to explore whether heterogeneity in results was in part explained by differences in 96 patient subpopulations. Finally, the coagulation parameters of our own cohort were included 97 in a systematic meta-analysis of published studies.

⁹⁸**² Materials and Methods**

99 In this study, we aimed to identify the relationship between coagulation biomarkers taken at 100 admission and severity of COVID-19 in adult (>18) patients by estimating the effect size of 101 five laboratory coagulation tests: D-dimers, platelets, fibrinogen, activated partial 102 thromboplastin time, and prothrombin time.

¹⁰³**2.1 Search Strategy, Exclusion and Inclusion criteria**

¹⁰⁴To broaden our search, we included Ovid, PubMed, Web of Sciences, and Google Scholar 105 in the study. They were thoroughly scanned using the following keywords: SARS-CoV-2, ¹⁰⁶COVID-19, coagulation, severity, characteristics, features, D-dimers, platelets, fibrinogen, 107 cohort, observational, retrospective. First, satisfying search results were exported to an Excel 108 table and duplicates were eliminated. Second, we conducted a preliminary review of retrieved 109 articles' abstracts. Papers that focused on pregnant women, children, or specific age groups 110 were avoided. Similarly, works that focused on the effect of medical treatment or patients 111 with particular commodities were not included in the meta-analysis. We also excluded studies 112 that compared mortality among groups of COVID-19 patients. Then, each publication was ¹¹³checked according to the inclusion criteria: sample size, severity assessment criteria, presence 114 of at least one coagulation marker of interest expressed as a continuous variable. To be 115 included, a study should have had more than 15 patients and divided them according to the

116 disease severity - WHO guidelines, ICU admission, disease aggravation, or need for oxygen 117 therapy. Next, a list of biomarkers should have included at least some of the coagulation 118 parameters: platelets count (PLT), D-dimers (DD), fibrinogen (FIB), activated partial 119 thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), Activated 120 thrombin (AT), Factor VIII (FVIII), and Von Willebrand factor (vWF). Finally, the quality of 121 selected articles was assessed with the NIH Quality Assessment Tool for Observational 122 Cohort and Cross-Sectional studies. Questions 5, 6, 12, 13 were not applicable to selected 123 studies due to their observational/retrospective nature; Question 8 was not applicable to 124 studies with dichotomous exposure values, like ICU admission and need for oxygen therapy. 125 Hence, studies with a quality score of less than five were excluded from the analysis. Search, 126 and quality check were conducted independently by two authors. Disagreements were 127 resolved during a joint discussion with a third author.

¹²⁸**2.2 Data extraction**

¹²⁹The primary goal was to retrieve from each article data about two groups of patients 130 differing by disease severity: group size, stratification criteria, results of the laboratory tests. ¹³¹Apart from these, we kept a record of the country, hospital, and admission time in order to 132 identify and exclude duplicate patients.

¹³³**2.3 Cohort from the National Research Center for Cardiac Surgery**

¹³⁴**2.3.1 Participants and data collection**

¹³⁵From a large cohort of 560 patients consecutively admitted from June 2020 to August 2021 136 due to coronavirus infection to the cardiology department of the NCJSC "National Research" 137 Center for Cardiac Surgery" (NRCCS), Nur-Sultan, Kazakhstan, we selected 451 patients 138 with a confirmed diagnosis of COVID-19, aged \geq 18 years, and those with the onset of the 139 disease \leq 21 days, all of whom were hospitalized for at least 24 hours with COVID-19. All 6

¹⁴⁰demographic, clinical, laboratory data were extracted from the electronic records of the ¹⁴¹NRCSC. Laboratory tests included PLT, PT, international normalized ratio, APTT, FIB, DD. ¹⁴²Blood samples were collected at admission by the clinical team. Clotting tests were 143 performed according to standard methods. For coagulation tests (PT, international normalized 144 ratio, APTT, FIB), we used AVATUBE® with sodium citrate, and it was measured on ¹⁴⁵Sysmex CS-2500 (Sysmex, Japan). Blood for DD was collected in AVATUBE® with 146 sodium citrate, and D-dimers were quantified on Cobas® 6000. PLT counts were measured 147 on Sysmex XS-500 (Sysmex, Japan) with blood collection performed in AVATUBE® with ¹⁴⁸K2 EDTA. The confirmation of SARS-CoV-2 infection was done by real-time quantitative 149 reverse-transcription polymerase chain reaction (RT-PCR) assay on nose/throat swab or 150 sputum samples using CFX96® Real-Time System (Bio-Rad Laboratories, Inc., USA).

¹⁵¹**2.3.2 Clinical assessment**

152 The COVID-19 population was initially divided into four groups according to disease 153 severity following local guidelines "Diagnosis and treatment of Covid-19 in Adults" ¹⁵⁴(http://www.rcrz.kz/index.php/ru/2017-03-12-10-51-13/klinicheskie-protokoly) (**Suppl. File** ¹⁵⁵**1**). The study protocol was approved by the medical ethics committee of the National 156 Research Center for Cardiac Surgery, Nur-Sultan, Kazakhstan waiving the need for written 157 informed consent due to the retrospective design.

¹⁵⁸**2.4 Data analysis**

¹⁵⁹**2.4.1 Data transformation**

All data analysis was performed in the RStudio 1.4.1717 with R version 4.1.0 (Integrated 161 Development Environment for R. RStudio, PBC, USA). In the most of cases, results were ¹⁶²reported as the first, second (median), and third quartiles, reflecting that original data was not ¹⁶³normally distributed. The "estmeansd" package was used to convert median, interquartile 164 range, minimum and maximum values to mean and standard deviation. The package

¹⁶⁵implements Box Cox transformation to normalize raw data prior to conversion. Then, Lou ¹⁶⁶(2018) formulas for mean and Wan (2014) formulas for standard deviation are used. Since 167 the criteria and number of groups differed from study to study, patients had to be regrouped 168 into the more and less severe groups accordingly: severe/critical and mild/moderate, ICU 169 admitted patients and outpatients/general ward patients, observed aggravation and 170 recovery/stable, and need for oxygen therapy.

¹⁷¹**2.4.2 Meta-analysis**

172 The "meta" and "metafor" packages were used for the meta-analysis. Heterogeneity was 173 assessed using the I^2 , tau-squared, and prediction intervals. Following the recommendations 174 of Veroniki (2016), Paule-Mandel (PM) tau-squared estimator and Q-Profile (QP) tau-175 squared confidence interval estimator were used in this meta-analysis. To account for 176 different measurement scales and possible inaccuracy of the Graph Digitizer, the standardized 177 mean difference (SMD), or Hedges g, based on the inverse-variance approach, was estimated. 178 For datasets with high heterogeneity, the Knapp-Hartung adjusted random-effects model is 179 implemented. In case of low heterogeneity, the fixed-effects model is applied.

¹⁸⁰**2.4.3 Sensitivity and Subgroup analysis**

¹⁸¹We also performed several sensitivity analyses using the "dmetar" package. First, we 182 recalculated the effect size using the leave-one-out method. Second, basic outliers, studies ¹⁸³whose confidence intervals do not overlap with the pooled effect confidence interval, were 184 removed. Third, we ran the diagnostic for influential cases with Graphic Display of Study ¹⁸⁵Heterogeneity (GOSH) plots and excluded them from the meta-analysis. To further explore 186 the heterogeneity of the data, we conducted subgroup analyses: based on grouping criteria 187 and location.

¹⁸⁸**2.5 Publication Bias**

- 189 We used the counter-enhanced Funnel plots and Egger's test by linear regression to assess
- 190 the possibility for publication bias in selected studies.

191

¹⁹²**Figure 1.** Flow diagram illustrating the process of data collection.

193

```
1943 Results
```
¹⁹⁵**3.1 Results of the Web Search**

196 The stepwise process of selection is depicted in Figure 1. Initially, there were 4056 papers 197 that matched search parameters. After the removal of duplicates and studies that did not meet 198 the exclusion criteria, only 195 unique studies remained. A more thorough review based on 199 the inclusion criteria has proven 125 studies to be unfitting. In addition to 70 that were left,

200 15 studies were extracted from the references lists of previously published meta-analyses and 201 systematic reviews. Finally, we performed a quality check and removed duplicate patients, ²⁰²which resulted in 40 being included into the meta-analysis. Besides original articles, we have 203 included data from the National Research Center for Cardiac Surgery located in Nur-Sultan, ²⁰⁴Kazakhstan. This data set included data from 451 patients with acute COVID-19.

²⁰⁵**3.2 Description of Selected Studies**

206 Overall, this meta-analysis comprises 17601 patients from 40 research papers and the ²⁰⁷NRCSC. Of the total, 24 studies originated from China, while the rest included data from ²⁰⁸France, Germany, Italy, Mexico, Singapore, South Korea, Turkey, UK, and the USA. Most of 209 the articles (23) reported division of patients according to the WHO guidelines. Out of the 210 rest, 12 articles made groups based on the ICU admission, 3 focused on disease aggravation, 211 and 3 on the need for oxygen therapy. This information is depicted in **Figure 2** in more 212 detail.

²¹⁴**Figure 2.** Diagram depicting characteristics of selected studies: (**A**) number of publications 215 per country, (**B**) number of patients per country, (**C**) number of publications per severity 216 assessment criterion. The latter (C) indicates the total number of research articles to be 42 217 instead of 41 because one study reported two populations of patients admitted to the hospital 218 at different periods.

²¹⁹**3.3 Results of Meta-analysis**

²²⁰**3.3.1 Pooled Effect Sizes**

²²¹We collected data for five coagulation parameters: PLT, DD, FIB, APTT, and PT. In all 222 cases, the heterogeneity was extremely high $(I^2 > 80\%)$, so the Knapp-Hartung adjusted 223 random-effects model was applied in all parts of the meta-analysis. DD, FIB, APTT, and PT ²²⁴were significantly higher in more severe cases (SMD 0.6985 with 95%CI [0.5155; 0.8815]; 225 SMD 0.661 with 95%CI [0.3387; 0.9833]; SMD 0.2683 with 95%CI [0.1357; 0.4009]; SMD 226 0.284 with 95%CI [0.1472; 0.4208]). In contrast, PLT was significantly lower in patients 227 with severe cases of COVID-19 (SMD -0.1684 with 95%CI [-0.2826; -0.0542]). Forest plots ²²⁸for the meta-analyses are shown in **Figures 3-4**, and results are highlighted in **Table 1**.

231

232

B D-dimer

233

²³⁴**Figure 3.** Forest plot of association between COVID-19 severity and platelets (**A**), D-dimers

²³⁵(**B**).

A Fibrinogen

B Activated partial thromboplastin time

C Prothrombin time

236

- ²³⁷**Figure 4.** Forest plots of the association between COVID-19 severity and: (**A)** fibrinogen,
- ²³⁸(**B)** activated partial thromboplastin time, (**C)** prothrombin time.

²³⁹**Table 1.** Summary of the effect sizes for all coagulation parameters

²⁴¹**3.3.2 Sensitivity and Subgroup Analysis**

242 Neither the analysis by the leave-one-out method nor the influence diagnostic has identified 243 studies that solely cause a significant change in the effect size estimates. Removal of several 244 outliers based on the pooled and individual confidence intervals allowed significant decrease 245 in heterogeneity, yet it did not affect the interpretation of the results. Adjusted effect sizes ²⁴⁶and heterogeneity measurements are summarized in **Table 2**. All influence diagnostic plots, 247 such as Baujat and leave-one-out plots, Cook's distance, Covariance Ratio, etc., are provided 248 in the **Suppl. Figures 1-16** along with resulting Forest plots.

GOSH plots were built for all five models. K-means, DBSCAN, and Gaussian Mixture Model were implemented as clustering methods. This diagnostic was not applied on PLT and DD since they only have one cluster each (**Figure 5**); for FIB, APTT, and PT, on the other 252 hand, we constructed the plots and identified several possible influential cases. Original GOSH plots for these parameters are given at **Suppl. Figures**. For fibrinogen, models that 254 include studies by Fu et al. (2020) and Wang et al. (2020) tend to show higher heterogeneity and greater effect size (**Figure 6A-B**). For activated partial thromboplastin time, GOSH plot 256 demonstrated that studies by J. Zhao et al. (2021), H. Zhang et al (2020), and Yu et al. (2020) increase model's heterogeneity and slightly pull the effect size to the left (**Figure 6C-E**).

²⁵⁸GOSH plots of the prothrombin time effect size identified four studies, three of which (J. ²⁵⁹Zhao et al (2021), Cugno et al. (2021), and Zhou et al. (2021) pull effect size to the left ²⁶⁰(**Figure 6F-H**), and one (Bastug et al.) pulls effect size to the right (**Figure 6I**). We've 261 excluded these studies and recalculated the pooled effect size for each parameter. Results are 262 summarized in **Table 2**.

²⁶³To explore the possible sources of heterogeneity and test the robustness of our data, we 264 have conducted subgroup analyses based on articles' country of origin and criteria for ²⁶⁵severity stratification. Results are summarized in **Table 3**. Subgroup analysis showed no 266 significant difference between articles originated from different countries but revealed that 267 severity assessment criteria might have an influence on overestimated effect sizes for PLT 268 and DD. High heterogeneity levels seem to be persistent oven different subgroups. Being the 269 only exception, values of APTT obtained from non-Chinese articles were less heterogenous -270 47.1% compared to 84.7% in studies originated in China.

²⁷²**Figure 5.** GOSH diagnostic for influential cases in meta-analysis models (**A) -** PLT, (**B) -** 273 DD.

²⁷⁵**Figure 6.** GOSH plots fixed for influential studies in meta-analysis models. (**A-B)** -

276 fibrinogen; (C-E) - APTT; (F-I) - prothrombin time.

274

278

²⁷⁹**Table 2.** Summary results of the sensitivity analysis

280

281
282

²⁸³**Table 3.** Summary results of the subgroup analysis

284 284

²⁸⁵**3.3.3 Publication Bias**

²⁸⁶Contour-enhanced funnel plots for five coagulation parameters are depicted in **Figure 7**, 287 and the results of Egger's test are summarized in **Table 4**. Based on the linear regression 288 results, significant asymmetry is observed in published studies that included results for PLT, ²⁸⁹DD (Intercept [p-value]: -1.297 [0.0336], 3.182 [0.0013]), and somewhat significant 290 asymmetry was indicated for FIB (1.872 [0.0493]). While it is impossible to predict whether 291 asymmetry is coming solely from publication bias, contour-enhanced funnel plots for DD and ²⁹²FIB (**Figure 6B-C**) show that the number of papers with insignificant findings is very small 293 ($p > 0.1$). This may advocate for the presence of some publication bias. In contrast, **Figure** ²⁹⁴**6A** illustrates that even though the funnel plot for PLT has some asymmetry, there are plenty 295 of publications with insignificant SMDs, thus decreasing the possibility of publication bias.

²⁹⁶To further explore the robustness of our findings, we have conducted several additional 297 tests. As reported by Zwetsloot (2017) and his colleagues, plotting SMD against its standard 298 error to assess the publication bias can result in distorted funnel plots, leading to false-299 positive conclusions. Since SMD is necessary for our analysis and cannot be substituted, we 300 used a sample size-based precision estimate instead of the standard error – $1/\sqrt{n}$. The resulting 301 funnel plots (**Supplemental Figure 16**) showed no significant distortion.

³⁰²Similar corrections were made to Egger's test: since standardized mean difference and 303 standard error are not independent, we can expect the test to yield some false-positive results.

³⁰⁴In our calculations, we used the corrected SE suggested by Pustejovsky and Rodgers (2019). ³⁰⁵Results are given in the **Supplemental Table 2.** The only model that was affected by this 306 correction was FIB (intercept 2.142 with a p-value of 0.0526 compared to the initial 1.872 307 and 0.0493), indicating that previously concluded asymmetry might have been a false 308 positive. Interpretation of results for other parameters remained the same.

³¹⁰**Figure 7.** Contour-enhanced funnel plots evaluating the presence of publication bias in the

311 pool of articles that report association between COVID-19 severity and (**A)** platelets; (**B)** D-

³¹²dimer; (**C)** fibrinogen; (**D)** activated partial thromboplastin time; (**E)** prothrombin time.

³¹⁵**4. Discussion**

316 There is a need to identify early indicators of the risk of critical patients progressing to 317 ICU at COVID-19. Abnormal coagulation parameters, including DD and FIB levels, changes 318 in PLT, and PT, are observed in many patients with COVID-19 infection at admission (rev. ³¹⁹Levi et al., 2020; Iba et al., 2020). However, as discussed by different authors, these 320 indicators provide contradictory information regarding risk stratification and prognosis (Luo 321 et al., 2020; Tang et al., 2020; Ding et al., 2021). There are several previous meta-analysis 322 reviews researching abnormal coagulation and the severity of COVID-2019 infection. The ³²³majority of analyzed studies were conducted at the beginning of the pandemic and examined 324 the Chinese population of patients (before April 2020 - Xiong et al., 2020; Lippi et al., 2020; 325 Zhang et al., 2020; Zhu et al., 2021; June 2020 -Di Minno et al., 2020). Through our meta-326 analysis study, it was revealed that DD and FIB levels, APTC, and prothrombin time were ³²⁷significantly higher in the severe group of COVID-19 patients. In contrast, PLT was ³²⁸significantly lower in these patients. There was no evidence of effects across different 329 geographic subgroups, with the exception of APTT values.

330

³³¹**4.1 Platelet changes**

³³²In this meta-analysis, we systematically analyze evidence for the utility of lowered PLT ³³³levels on admission in the relationship to the severity of infection. Platelets play a crucial role 334 in the maintenance of hemostasis, contribute to thromboinflammatory processes (van der ³³⁵Meijden, Heemskerk, 2019) and at different stages of viral infection, changes in platelet 336 production or destruction may result in coagulation imbalances leading to pro-thrombotic 337 events or in platelet disfunction and bleeding risks (Assinger, 2014), and increased activation 338 of platelets (Hottz et al., 2020; Zaid et al., 2020; Althaus et al., 2021). Thrombocytopenia (platelet count $\langle 150x10^9/L \rangle$ seems to represent an important marker of COVID-19 severity ³⁴⁰(Qu et al., 2020; Yang et al., 2020; Lippi et al., 2020; Iba et al., 2020) and mortality outcome ³⁴¹(Lippi et al., 2020; Yang et al., 2020). The reasons for a thrombocytopenia are multi-factorial, ³⁴²which may include early suppression of megakaryocytes production and damage in bone ³⁴³marrow and lungs, hemophagocytosis, immune destruction of platelets and other reasons. ³⁴⁴Significant thrombocytopenia in COVID-19 is less frequent than it was reported for the 345 largest SARS-1 cohort (45%) (Lee et al., 2003). SARS-1 induced platelet depletion was 346 related to direct infection of megakaryocytes and hematopoietic progenitors (rev. by Yang et ³⁴⁷al., 2005). However, almost half of patients presented thrombocytosis following initial 348 thrombocytopenia during SARS epidemics in 2003 (Wong et al., 2003). Recently, a different 349 trend in platelet changes in COVID-19 patients with immune thrombocytic purpura (ITP) was 350 reported by Cruz-Benito et al. (2021). Secondary to SARS-CoV2 infection in ITP-patients 351 generally develops early thrombocytosis (Cruz-Benito et al., 2020). Only a few cases of 352 thrombocytosis (in children) were reported during SARS-CoV2 pandemics (Feld et al., 2020) ³⁵³as part of a multisystem inflammatory syndrome in children associated with COVID-19 ³⁵⁴(MIS-C) (Yasuhara et al., 2020). It is possible that opposite PLT changes may reflect 355 different phases of COVID-19 infection (Thachil et al., 2020) – acute and convalescent 22

356 phases, though the explanation has not been established yet. The reactive thrombocytosis that ³⁵⁷may occur during the convalescent phase requires time observation that would include a 358 period preceding patient discharge. The increase of immature reticulated platelets reported 359 recently in COVID-19 patients by different groups (Cohen et al., 2021; Welder et al., 2021) ³⁶⁰may play a role in the limiting of effectiveness of anti-platelet therapies (Guthikonda et al., ³⁶¹2007; Ibrahim et al., 2012; Armstrong et al., 2017). Change in platelets parameters (increased 362 mean volume) (Lippi et al., 2021) and reactivity are suggested to be associated with a severe 363 COVID-19 infection (Hottz et al., 2020; Yatim et al., 2021).

³⁶⁴**4.2 DD and FIB levels, and Thromboembolic complications**

365 Concordant with other studies, we found DD and FIB levels significantly elevated in 366 severe COVID-19 infection, though DD levels results may suffer from some publication bias 367 as revealed by meta-regression analysis. It may be related to the variability of DD assays used ³⁶⁸in the different studies: they are not directly comparable due to the difference in the 369 monoclonal antibodies used for tests (Olson et al., 2013; rev. Goodwin et al., 2017). As 370 confirmed by autopsy results, the elevated DD levels can be associated with fibrin deposits 371 within pulmonary extravascular space and alveoli (Fox et al., 2020), but they may be 372 nonspecific to intravascular fibrin formation (Hunt et al., 2020). High DD levels, together 373 with elevated neutrophils, were reported to be predictive factors of pulmonary embolism in 374 COVID-19 patients (Thoreu et al., 2021). Thromboembolic complications related to COVID-³⁷⁵19 are responsible for a substantial mortality rate (Lodigiani et al., 2020; Kunutsor, ³⁷⁶Laukannen, 2020; Piazza et al., 2020; Grillet et al., 2020). Whereas the highest burden of 377 thromboembolism is associated with patients in the ICU (Helms et al., 2020; Llitjos et al., ³⁷⁸2020; Klok et al., 2020), patients in non-ICU settings also bear a significant risk of these 379 complications, especially VTE (venous thromboembolism) (Lodigiani et al., 2020; 380 Spyropoulos et al., 2020), as well as pulmonary embolism (Thoreau et al., 2021). Klock and
23

381 colleagues (2020) report that in spite of thrombosis prophylaxis, a high incidence of 382 thrombotic complications in ICU patients is comparable with patients from other groups with ³⁸³DIC (disseminated intravascular coagulation). Moreover, multiple studies describe cerebral 384 venous thrombosis (CVT) associated with COVID-19 infection (Garaci et al., 2020; Baudar 385 et al., 2020). DD and FIB levels are elevated in COVID-19 and in thromboembolism, and 386 therefore as single tests are unspecific and unhelpful in the differentiation of these conditions. 387 In part, it may be explained by the involvement in abnormal coagulation at COVID-19 of ³⁸⁸different systems, including endothelial cells, complement activation, and hypofibrinolysis 389 resulting in changes undetected by routine tests (Holter et al., 2020; Cugno et al., 2021). The 390 dysfunction of endothelial cells with COVID-19 may contribute to excess thrombin 391 generation and fibrinolysis shutdown, which is associated with VTE, stroke and, renal failure ³⁹²(Wright et al., 2020). There are different suggestions for COVID-19 risk stratification related ³⁹³to changes in platelets and endothelial cells, such as increased proportion of immature 394 reticulated platelet fraction (Cohen et al., 2021; Welder et al., 2021) or CECs (circulating 395 endothelial cells) counts in the blood representing stressed cells detached from injured 396 vessels, reported in various inflammatory and infective diseases, and are indicative of disease 397 severity (Blann et al., 2006). They were significantly higher in COVID-19 patients admitted 398 to the ICU and positively correlated with the length of hospital stay (Guervilly et al., 2020). ³⁹⁹This marker is related to SARS-CoV2 directly infecting primary endothelial cells (Monteil et 400 al., 2020). Furthermore, there is some evidence of infection in endothelial cells in severe 401 cases of COVID-19 (Varga et al., 2020), including the presence of coronavirus particles in 402 the cytoplasm of endothelial cells on electron microscopy (Colmenero et al., 2020). Platelets 403 activation and endothelial cell damage in COVID-19 patients are also resulting in elevated 404 levels of extracellular vesicles (EVs) (Capellano et al., 2021) recently associated with 405 severity of disease (Krishnamachary et al., 2021).

⁴⁰⁶**4.3 Fibrinolysis shutdown requires evaluation outside conventional coagulation** ⁴⁰⁷**parameters**

408 Fibrinolysis shutdown is induced by severe COVID-19 infection (Tang et al., 2020; ⁴⁰⁹Wright et al., 2020; Collett et al., 2021) and is partly responsible for high DD and FIB levels. 410 Some pathophysiological changes may contribute to high procoagulant conditions secondary 411 to COVID-19 infection. Thus, low plasminogen levels (Correa et al., 2020), similar to 412 plasminogen-related fibrinolysis observed at other viral infections such as influenza infection ⁴¹³(Berri et al., 2013), may lead to a hypercoagulability state. A multiplexed analysis of ⁴¹⁴inflammation-related gene expression (249 genes from nCounter Inflammation panel; ⁴¹⁵NanoString Technologies, USA) revealed similarities between lung specimens in influenza ⁴¹⁶and Covid-19 groups (Ackermann et al., 2020). Depression of fibrinolysis was reported not 417 only in ICU patients with severe infection and clinical signs of thromboembolism (Wright et 418 al., 2020), but also in the general unselected ICU cohort (Correa et al., 2020; Collett et al., 419 2020; Nougier et al., 2020). Viscoelastic testing (ROTEM, tissue-type plasminogen activator ⁴²⁰(tPA) ROTEM, TEG) and evaluation of clot formation by Clot Waveworm analysis have 421 demonstrated a hypercoagulable state, characterized by increased clot stiffness and severely 422 impaired fibrinolysis (Nougier et al., 2020; Collett et al., 2020; Panigada et al., 2020; Pavoni 423 et al., 2020; Fan et al., 2021; Hulshof et al., 2021). Elevated routine coagulation parameters 424 taken at admission may help with initial differentiation of severe and non-severe COVID-19 425 patient groups, but they do not provide information about fibrinolysis shutdown.

426 Although our findings were consistent across different geographic groups, they were 427 tempered by significant heterogeneity. The DD, FIB, and PLT elevation trends speak about 428 the necessity of investigating the potential of additional specific biomarkers for stratification 429 of COVID-19 patients at risk for fibrinolytic shutdown and associated micro-and macro-430 vascular events. We suggest that thorough characterization of platelets including a proportion
25

431 of immature reticulated platelets and their size/mean volume parameters as well as a clot 432 formation testing requires to evaluate a risk of thromboembolic events in COVID-19 patients 433 groups.

⁴³⁴**5 Limitations of the study**

435 Our findings should be interpreted with some limitations. Firstly, most of the included 436 studies were either retrospective and observational by design, thus prone to recall or 437 misclassification bias. Second, such studies often imply recruitment by convenience 438 sampling, in which case the representativeness of a study is questioned. The random effects 439 model was used due to the high heterogeneity of research. In the context of this meta-440 analysis, several different endpoints were allowed: severity guidelines, ICU admissions, 441 oxygen therapy requirement, and disease aggravation. In an attempt to overcome this issue, ⁴⁴²we have conducted a subgroup analysis. Third, uncontrolled variables might also pose a ⁴⁴³limitation - both the disease severity and coagulation parameters can be affected by several ⁴⁴⁴potential confounding variables, such as comorbidities, age, etc. Some studies have reported ⁴⁴⁵their results in terms of quartiles or maximum and minimum values. The necessity to convert 446 values could potentially influence the results. Although sensitivity and subgroup analyses 447 were conducted, some residual heterogeneity may affect the interpretation of results. Finally, 448 the underlying mechanisms of coagulation markers at COVID-19 still need to be 449 investigated.

⁴⁵⁰**6 Conclusions**

451 Our findings support using a combination of coagulation parameters for risk stratification 452 of patients with COVID-19 infection at the time of admission. However, additional 453 evaluation using clotting formation methods or combination with platelet-specific biomarkers 454 requires. This information may help physicians triage patients with thromboembolism. An 26

⁴⁵⁵important consideration is an intermediate and long follow-up of COVID-19 patients. We

- ⁴⁵⁶hypothesize that increase in platelets turnover towards immature reticulated forms contribute
- 457 to hypercoagulability state at COVID-19 patients and their resistance to anti-platelet therapy.
- ⁴⁵⁸Future research should take in account change in platelet parameters and platelet
- 459 fragmentation leading to elevated levels of extracellular vesicles.

⁴⁶⁰**7 Data availability Statement**

461 Data are available by request from co-corresponding authors.

⁴⁶²**8 Conflict of Interest**

463 The authors declare no conflict of interest.

⁴⁶⁴**9 Author Contributions**

⁴⁶⁵P.L. - conceptualization, methodology, formal analysis, investigation, data curation, writing

466 original draft, G.I., Z.S., A.K. – methodology, data curation, formal analysis, investigation;

⁴⁶⁷A.T.T., M.M.S., A.S.D., M.M.A., M.S.B. - methodology, formal analysis, investigation, data

468 curation of NRCSC cohort, writing a draft; E.D.P., A.T.- methodology; analysis; funding,

⁴⁶⁹N.S.B. - conceptualisation, methodology, formal analysis, investigation, data curation,

470 writing a draft. M.S.B. and N.S.B.- supervision. All authors read and edit a final draft.

⁴⁷¹**10 Acknowledgments**

475 by OPCRP2020018 grants from Nazarbayev University.

⁴⁷²We are very grateful to Sadyk Khamitov and Aliya Sailybayeva from the Research 473 Department of National Research Center for Cardiac Surgery for their excellent 474 organizational help. N.S.B. and A.T. were supported by FDCRGP SSH2020028, and N.S.B.

⁴⁷⁶**11 Abbreviations**

 $\ddot{}$

⁴⁸⁶**12 References**

- 487 Ackermann, M., Verleden, S.E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., et al.
- ⁴⁸⁸(2020). Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N.

⁴⁸⁹Engl. J. Med. 383, 120-128. doi: 10.1056/NEJMoa2015432

⁴⁹⁰Aloisio, E., Chibireva, M., Serafini, L., Pasqualetti, S.S.F., Dolci, A., Panteghini, M., et al. ⁴⁹¹(2020). A comprehensive appraisal of laboratory biochemistry tests as major predictors of ⁴⁹²COVID-19 severity. Arch. Pathol. Lab. Med. 144, 1457-1464. doi: 10.5858/arpa.2020-0389-

493 sa

- 494 Althaus, K., Marini, I., Zlamal, J., Pelzl, L., Singh, A., Häberle, H., et al. (2021). Antibody-
- 495 induced procoagulant platelets in severe COVID-19 infection. Blood. 137, 1061–1071. doi: 496 10.1182/blood.2020008762
- 497 Armstrong, P.C., Hoefer, T., Knowles, R.B., Tucker, A.T., Hayman, M.A. et al. (2017) ⁴⁹⁸Newly formed reticulated platelets undertmine pharmacokinetically short-lived antiplatelet

- 499 therapies. Atherosclerosis, Thromb. Vascular Biol. 37, 949-956.
- 500 doi.org/10.1161/ATVBAHA.116.308763
- 501 Assinger, A. (2014). Platelets and infection-an emerging role of platelets in viral infection.
- 502 Front. Immunol. 5, 649. doi: 10.3389/fimmu.2014.00649
- 503 Bastug, A., Bodur, H., Erdogan, S., Gokcinar, D., Kazancioglu, S., Deniz, B., et al. (2020).
- ⁵⁰⁴Clinical and laboratory features of COVID-19: predictors of severe prognosis. Int.
- 505 Immunopharmacol. 88:106950. doi: 10.1016/j.intimp.2020.106950
- 506 Baudar, C., Duprez, T., Kassab, A., Miller, N., Rutgers, M.P. (2020). COVID-19 as
- 507 triggering co-factor for cortical cerebral venous thrombosis? J Neuroradiol. 2020, 30205–
- ⁵⁰⁸302144. doi: 10.1016/j.neurad.2020.06.008
- 509 Bauer, W., Galtung, N., Neuwinger, N., Kaufner, L., Langer, E., Somasundaram, R., et al.
- 510 (2021). A matter of caution: coagulation parameters in COVID-19 do not differ from patients
- 511 with ruled-out SARS-CoV-2 infection in the emergency department. TH Open. 5, e43-e55.
- 512 doi: 10.1055/s-0040-1722612
- 513 Becker, R.C., Sexton, C., Smyth, S. (2021). COVID-19 and biomarkers of thrombosis: focus
- 514 on von Willebrand factor and extracellular vesicles. J. Thromb. Thrombolysis. 1-10. doi: 515 10.1007/s11239-021-02544-x
- 516 Bergantini, L., Bargagli, E., d'Alessandro, M., Refini, R., Cameli, P., Galasso, L., et al. ⁵¹⁷(2021). Prognostic bioindicators in severe COVID-19 patients. Cytokine. 141, 155455. doi: 518 10.1016/j.cyto.2021.155455
- 519 Berri, F., Rimmelzwaan, G.F., Hanss, M., Albina, E., Foucault-Grunenwald, M.L., Le, V.B., 520 et al. (2013). Plasminogen controls inflammation and pathogenesis of influenza virus 521 infections via fibrinolysis. PLoS Pathog. 9, e1003229. doi: 10.1371/journal.ppat.1003229

- ⁵²²Blann, A.D., Woywodt, A., Bertolini, F., Bull, T. M., Buyon, J. P., Clancy, R. M., et al.
- ⁵²³(2005). Circulating endothelial cells. Thromb. Haemost. 93, 228-235. doi: 10.1160/TH04-09- ⁵²⁴⁰⁵⁷⁸
- 525 Cappellano, G., Raineri, D., Rolla, R., Giordano, M., Puricelli. C., Vilardo, B., et al. (2021)
- 526 Circulating platelet-derived extracellular vesicles are a hallmark of SARS-Cov-2 infection.
- 527 Cells 10, 85. 10.3390/cells10010085
- 528 Cen, Y., Chen, X., Shen, Y., Zhang, X., Lei, Y., Xu, C., et al. (2020). Risk factors for disease
- 529 progression in patients with mild to moderate coronavirus disease 2019 a multi-centre
- 530 observational study. Clin. Microbiol. Infect. 26, 1242-1247. doi: 10.1016/j.cmi.2020.05.04
- 531 Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. (2020). Epidemiological and
- 532 clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a
- 533 descriptive study. Lancet. 395, 507-513. doi: 10.1016/S0140-6736(20)30211-7
- ⁵³⁴Chen, N., Li, Y., Fan, H., Tian, A., Yuan, H., Jiang, Z., et al. (2020). Analysis of dynamic ⁵³⁵disturbance in blood coagulation function of patients with coronavirus disease 2019: a 536 retrospective observational study. Medicine. 99, e22635. doi: 510 537 10.1097/MD.0000000000022635
- 538 Chen, Q., Zheng, Z., Zhang, C., Zhang, X., Wu, H., Wang, J., et al. (2020). Clinical 539 characteristics of 145 patients with coronavirus disease 2019 (COVID-19) in Taizhou, 540 Zhejiang, China. Infection. 48, 543–551. doi: 10.1007/s15010-020-01432-5
- 541 Chen, Z., Zhang, F., Hu, W., Chen, Q., Li, C., Wu, L., et al. (2021). Laboratory markers 542 associated with COVID-19 progression in patients with or without comorbidity: A 543 retrospective Study. J. Clin. Lab. Anal. 35, e23644. doi: 10.1002/jcla.23644

- ⁵⁴⁴Cohen, A., Harari, E., Cipok, M., Laish-Farkash, A., Bryk, G., Yahud, E. et al. (2021).
- 545 Immature platelets in patients hospitalized with COVID-19. J. Thromb. Thrombolysis 51,
- ⁵⁴⁶608-616. doi.org/10.1007/s11239-020-02290-6
- 547 Collett, L.W., Gluck, S., Strickland, R.M., Reddi, B.J. (2021). Evaluation of coagulation
- 548 status using viscoelastic testing in intensive care patients with coronavirus disease 2019
- ⁵⁴⁹(Covid-2019): an observational point prevalence cohort study. Austr. Crit. Care. 34, 155-159.
- 550 doi: 10.1016/j.aucc.2020.07.003
- 551 Colmenero, I., Santonja, C., Alonso-Riano, M., Hernandez-Martin, A., Andina, D., Wiesner,
- ⁵⁵²T., et al. (2020). SARS-CoV2 endothelial infection causes COVID-19 chilblains:
- 553 histopathological, immunohistochemical and ultrastructural study of seven paediatric cases.
- 554 Br. J. Dermatol. 183, 729-737. doi: 10.1111/bjd.19327
- 555 Correa, T.D., Cordioli, R.L., Guerra, J.C.C., da Silva, B.C., Rodrigues, R.R., de Souza, G.M.,
- 556 et al. (2020). Coagulation profile of COVID-19 patients admitted to the ICU: exploratory
- 557 study. PLoS ONE. 15, e0243604. doi: 10.1371/journal.pone.0243604
- 558 Creel-Bulos, C., Auld, S.C., Caridi-Scheible, M., Barker, N.A., Friend, S., Gaddh, M., et al.
- ⁵⁵⁹(2021). Fibrinolysis shutdown and a thrombosis in a COVID-19 ICU. Shock. 55, 316-320.
- 560 doi: 530 10.1097/SHK.000000000000163
- 561 Cruz-Benito, B., Rivas-Pollmar, M.I., Roman, M.T.A., Trelles-Martinez, R., Martin-Salces,
- 562 532 M., Lazaro-del Campo, P. et al. (2020). Paradoxical effect of SARS-CoV2 infection with
- ⁵⁶³immune thrombocytopenia. Br. J. Haematol. 192, 973-977. doi: 10.1111/bjh.17077
- 564 Cugno, M., Meroni, P. L., Gualtierotti, R., Griffini, S., Grovetti, E., Torri, A., et al. (2021).
- ⁵⁶⁵Complement activation and endothelial perturbation parallel COVID-19 severity and activity.
- 566 J. Autoimmun. 116, 102560. doi: 10.1016/j.jaut.2020.102560

- 567 Demelo-Rodriguez, P., Cervilla-Munoz, E., Ordieres-Ortega, L., Parra-Virto, A., Toledano-
- ⁵⁶⁸Macias, M. et al. (2020). Influence of asymptomatic deep vein thrombosis in patients with
- ⁵⁶⁹COVID-19 pneumonia and elevated D-dimers levels. Thrombosis Res. 192, 23-26. doi:
- 570 10.1016/j.thromres.2020.05.018
- 571 Di Micco, P., Russo, V., Carannante, N., Imparato, M., Cardillo, G., and Lodigiani, C.
- ⁵⁷²(2020). Prognostic value of fibrinogen among COVID-19 patients admitted to an emergency
- 573 department: an Italian cohort study. J. Clin. Med. 9, 4134. doi: 10.3390/jcm9124134
- 574 Di Minno, M.N.D., Calcaterra, I., Lupoli, R., Storino, A., Spedicato, G.A., Maniscalco, M. et
- 575 al. (2020) Hemostatic changes in patients with COVID-19: a meta-analysis with meta-
- 576 regressions. J. Clin. Med. 9, 2244; doi:10.3390/jcm9072244
- 577 Ding, R., Yang, Z., Huang, D., Wang, Y., Li, X., Zhou, X., et al. (2021). Identification of
- 578 parameters in routine blood and coagulation tests related to the severity of COVID-19. Int. J.
- 579 Med. Sci. 18, 1207–1215. doi: 10.7150/ijms.47494
- 580 Doevelaar, A. A., Bachmann, M., Hölzer, B., Seibert, F. S., Rohn, B. J., Bauer, F., et al. ⁵⁸¹(2021). Von Willebrand factor multimer formation contributes to immunothrombosis in 582 Coronavirus disease 2019. Critical Care Med. 49, e512-e520. doi:
- 583 10.1097/CCM.00000000000004918
- 584 Fan, B. E., Ng, J., Chan, S.S.W., Christopher, D., Tso, A.C.E., Ling, A.M. et al. (2021).
- ⁵⁸⁵COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state
- 586 demonstrated by parameters of haemostasis and clot waveform analysis. J. Thromb.
- 587 Thrombolysis 51, 663-674. doi.org/10.1007/s11239-020-02318-x

- ⁵⁸⁸Feld, L., Belfer, J., Kabra, R., Goenka, P., Rai, S., Moriarty, S., et al. (2020). A case series of
- 589 the 2019 novel coronavirus (SARS-CoV-2) in 3 febrile infants in New York. Pediatrics.146,
- ⁵⁹⁰e20201056. doi: 10.1542/peds.2020-1056
- 591 Fox, S.E., Akmatbekov, A., Harbert, J.L., Li, G., Brown, J.Q., and Vander Heide, R.S.
- ⁵⁹²(2020). Pulmonary and cardiac pathology in African American patients with COVID-19: an
- 593 autopsy series from New Orleans. Lancet Respir. Med. 8, 681–686. doi: 10.1016/S2213-⁵⁹⁴2600(20)30243-5
- ⁵⁹⁵Fu, J., Kong, J., Wang, W., Wu, M., Yao, L., Wang, Z., et al. (2020). The Clinical 596 implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: a 597 retrospective study in Suzhou China. Thromb. Res. 192, 3-8. doi: 598 10.1016/j.thromres.2020.05.006
- ⁵⁹⁹Garaci, F., Di Giuliano, F., Picchi, E., Da Ros, V., and Floris, R. (2020). Venous cerebral ⁶⁰⁰thrombosis in COVID-19 patient. J. Neurol. Sci. 414, 116871. doi: ⁶⁰¹10.1016/j.jns.2020.116871
- ⁶⁰²Gerotziafas, G. T., Sergentanis, T. N., Voiriot, G., Lassel, L., Papageorgiou, C., Elabbadi, A.,
- ⁶⁰³et al. (2020). Derivation and validation of a predictive score for disease worsening in patients
- ⁶⁰⁴with COVID-19. Thromb. Haemost. 120, 1680-1690. doi: 10.1055/s-0040-1716544
- ⁶⁰⁵Giannis, D., Ziogas, I.A., and Gianni, P. (2020). Coagulation disorders in coronavirus 606 infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J. Clin.
- 607 Virol. 127, 104362. doi: 10.1016/j.jcv.2020.104362
- 608 Goeijenbier, M., Van Wissen, M., Van De Weg, C., Jong, E., Gerdes, V. E. A., Meijers, J. C.
- ⁶⁰⁹M., et al. (2012). Review: viral infections and mechanisms of thrombosis and bleeding. J.
- ⁶¹⁰Med. Virol. 84, 1680-1696. doi: 10.1002/jmv.23354

- 611 Goodwin, A.J., Higgins, R.A., Moser, K.A., Smock, K.J., Chandler, V.L., Kottke-Marchant,
- ⁶¹²K., et al. (2017). Issues surrounding age-adjusted D-dimer cutoffs that practicing physicians
- 613 need to know when evaluating patients with suspected pulmonary embolism. Ann. Intern.
- ⁶¹⁴Med. 166, 361–364. doi: 10.7326/M16-2030
- 615 Goshua, G., Pine, A.B., Meizlish, M.L., Chang, C.-H., Zhang, H., Bahel, P. et al (2020).
- 616 Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre,
- ⁶¹⁷cross-sectional study. Lancet Haematol. 7, e575–e582. doi: 10.1016/S2352 3026(20)30216-7
- ⁶¹⁸Grillet, F., Behr, J., Calame, P., Aubry, S., and Delabrousse, E. (2020). Acute pulmonary
- 619 embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography.
- ⁶²⁰Radiology. 23, 201544. doi: 10.1148/radiol.2020201544
- 621 Guervilly, C., Burtey, S., Sabatier, F., Cauchois, R., Lano, G., Abdili, E., et al. (2020).
- ⁶²²Circulating endothelial cells as a marker of endothelial injury in severe COVID-19. J. Infect.
- 623 Dis. 222, 1789-1793. doi: 10.1093/infdis/jiaa528
- ⁶²⁴Guthikonda, S., Lev, E.I., Patel, R., DeLao, T., Bergeron, A.L., Dong, J.F., et al. (2007)
- 625 Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of
- 626 aspirin. J. Thromb. Haemost. 5, 490-496. doi:10.1111/j.1538-7836.2007.02387.x
- 627 Helms, J., Tacquard, C., Severac, F., Leonard-Lorant, I., Ohana, M., Delabranche, X., et al.
- ⁶²⁸(2020). High risk of thrombosis in patients with severe SARS-CoV2-infection: a multicenter
- 629 prospective cohort study. Intens. Care Med. 46, 1089-1098. doi: 10.1007/s00134- 020-06062-
- 630 x
- 631 Higuera-de-la-Tijera, F., Servín-Caamaño, A., Reyes-Herrera, D., Flores-López, A., Robiou
- ⁶³²Vivero, E., Martínez-Rivera, F., et al. (2021). The Age-AST-D Dimer (AAD) regression

⁶³³model predicts severe COVID-19 disease. Dis. Markers. 2021:6658270. doi: ⁶³⁴10.1155/2021/6658270

- ⁶³⁵Holter, J.C., Pischke, S.E., de Boer, E., Lind, A., Jenum, S., Holten, A.R. et al. (2020).
- 636 Systemic complement activation is associated with respiratory failure in COVID-19 patients.
- 637 Proc. Natl. Acad. USA 117, 25018-25025
- ⁶³⁸Hottz, E.D., Azevedo-Quintanilha, I.G., Palhinha, L., Teixeira, L., Barretto, E.A., Pao,
- ⁶³⁹C.R.R. et al. (2020). Platelet activation and platelet-monocyte aggregate formation trigger 640 tissue factor expression in patients with severe COVID-19. Blood 136, 1330-1341. ⁶⁴¹https://doi.org/10.1182/blood.2020007252
- ⁶⁴²Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020). Clinical features of
- 643 patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 10223. doi: ⁶⁴⁴10.1016/s0140-6736(20)30183-5
- ⁶⁴⁵Hulshof, A.-M., Brueggemann, R.A.G., Mulder, M.M.G., van de Berg, T.W., Sels, J.-W.
- ⁶⁴⁶E.M., Olie, R.H. (2021) Serial EXTEM, FIBTEM, and tPA Rotational thromboelastometry
- 647 observations in the Maastricht Intensive Care COVID Cohort persistence of
- 648 hypercoagulability and hypofibrinolysis despite anticoagulation. Front. Cardiovasc. Med. 8,
- ⁶⁴⁹654174. doi: 10.3389/fcvm.2021.654174
- ⁶⁵⁰Hunt, B.J., Levi, M. (2020). The source of elevated plasma D-dimer levels in COVID-19 651 infection. Br. J. Haematol. doi: 10.1111/bjh.16907
- ⁶⁵²Hwang, D. M., Chamberlain, D. W., Poutanen, S. M., Low, D. E., Asa, S. L., and Butany, J.
- ⁶⁵³(2005). Pulmonary pathology of severe acute respiratory syndrome in Toronto. Modern.
- 654 Pathol. 18, 1–10. doi: 10.1038/modpathol.3800247

- Ibrahim, H., Nadipalli, S., DeLao, T., Guthikonda, S., Kleiman, N.S. (2012) Immature
- 659 platelet fraction (IPF) determined with an automated method predicts clopidogrel
- hyporesponsiveness. J. Thromb. Thrombolysis 33, 137–42. doi:10.1007/s11239-011-0665-7.
- 661 Johns Hopkins University & Medicine (2021). The Johns Hopkins Coronavirus Resource
- 662 Center (CRC). https://coronavirus.jhu.edu/ [Accessed September 30, 2021].
- Karakoyun, I., Colak, A., Turken, M., Altin, Z., Arslan, F. D., Iyilikci, V., et al. (2021).
- Diagnostic utility of C-reactive protein to albumin ratio as an early warning sign in
- hospitalized severe COVID-19 patients. Int. Immunopharmacol. 91, 107285. doi: 10.1016/j.intimp.2020.107285
- Klok, F.A., Kruip, M.J.H.A., Van der Meer, N.J.M., Arbous, M.C., Gommers, D.A.M.P.J. et
- al. (2020). Incidence of thrombotic complications in critically ill ICU patients with COVID-
- 19. Thrombosis Res. 191, 145-147. doi: 10.1016/j.thromres.2020.04.013
- Krishnamachary, B., Cook, S., Kumar, A., Spikes, L., Chalise, P., Dhillon, N.K. (2021)
- Extracellular vesicle-mediated endothelial apoptosis and EV-associated proteins correlate
- 672 with COVID-19 disease severity. J. Extracel. Vesicles. 10, e12117. doi: 10.1002/jev2.12117
- Kunutsor, S.K., and Laukkanen, J.A. (2020). Incidence of venous and arterial
- 674 thromboembolic complications in COVID-19: a systematic review and meta-analysis.
- Thrombosis Res. 196, 27-30. doi: 10.1016/j.thromres.2020.08.022

- ⁶⁷⁶Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G.M., et al. (2003). A major outbreak
- 677 of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348, 1986–94. ⁶⁷⁸https://doi.org/10.1056/NEJMoa030685
- 679 Levi, M., and Scully, M. (2018). How I treat disseminated intravascular coagulation. Blood.
- ⁶⁸⁰131, 845-854. doi: 10.1182/blood-2017-10-804096
- 681 Levi, M., Thachil, J., Iba, T., Levi, J.H. (2020). Coagulation abnormalities and thrombosis in 682 patients with COVID-19. Lancet Haematol. 7, e438-440. doi: 10.1016/ S2352-⁶⁸³3026(20)30145-9
- ⁶⁸⁴Liao, D., Zhou, F., Luo, L., Xu, M., Wang, H., Xia, J., et al. (2020). Haematological
- 685 characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a
- 686 retrospective cohort study. Lancet Haematol. 7, e671-e678. doi: 10.1016/s2352-⁶⁸⁷3026(20)30217-9
- ⁶⁸⁸Lippi, G., Plebani, M., and Henry, B.M. (2020). Thrombocytopenia is associated with severe
- 689 coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin. Chim. Acta 506,
- ⁶⁹⁰145–148. doi:10.1016/j. cca.2020.03.022
- 691 Lippi, G., Henry, B.M., Favaloro, E.J. (2021). Mean platelet volume predicts severe COVID-
- 692 19 illness. Semin. Thromb. Hemost. 47, 456-459 ⁶⁹³DOI: 10.1055/s-0041-1727283
- ⁶⁹⁴Liu, J., Liu, Z., Jiang, W., Wang, J., Zhu, M., Song, J., et al. (2020a). Clinical predictors of
- ⁶⁹⁵COVID-19 disease progression and death: analysis of 214 hospitalized patients from Wuhan,
- 696 China. Clin. Res. J. 15, 293-309. doi: 10.1111/crj.13296

- ⁶⁹⁷Liu, J., Zhang, S., Wu, Z., Shang, Y., Dong, X., Li, G., et al. (2020b). Clinical outcomes of
- ⁶⁹⁸COVID-19 in Wuhan, China: a large cohort study. Ann. Intensive Care. 10, 1-21. doi:
- ⁶⁹⁹10.1186/s13613-020-00706-3
- ⁷⁰⁰Liu, J., Tu, C., Zhu, M., Wang, J., Yang, C., Liu, W., and Xiong, B. (2021). The Clinical
- 701 course and prognostic factors of severe COVID-19 in Wuhan, China. Medicine. 100: e23996.
- 702 doi: 10.1097/md.0000000000023996
- ⁷⁰³Liu, W., Tao, Z. W., Wang, L., Yuan, M. L., Liu, K., Zhou, L., et al. (2020). Analysis of
- ⁷⁰⁴factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus

705 disease. Chin. Med. J. 133, 1032–1038. doi: 10.1097/cm9.00000000000000775

- ⁷⁰⁶Llitjos, J.-F., Leclerc, M., Chochois, C., Monsallier, J.-M., Ramakers, M., Auvray, M., et al.
- 707 (2020). High incidence of venous thromboembolic events in anticoagulated severe COVID-
- ⁷⁰⁸19 patients. J. Thromb. Haemost. 18, 1743-1746. doi: 10.1111/jth.14869
- ⁷⁰⁹Lodigiani, C., Iapichino, G., Carenzo, L., Cecconi, M., Ferrazzi, P., Sebastian, T., 710 et al. (2020). Venous and arterial thromboembolic complications in COVID \Box 19 patients ⁷¹¹admitted to an academic hospital in Milan, Italy. Thromb. Res. 191, 9–14. doi: 712 10.1016/j.thromres.2020.04.024
- 713 Long, H., Nie, L., Xiang, X., Li, H., Zhang, X., Fu, X., et al. (2020). D-Dimer and 714 prothrombin time are the significant indicators of severe COVID-19 and poor prognosis.
- 715 Biomed. Res. Int. 2020, 6159720. doi: 10.1155/2020/6159720
- 716 Lopez-Castaneda, S., García-Larragoiti, N., Cano-Mendez, A., Blancas-Ayala, K., Damian-717 Vázquez, G., Perez-Medina, A. I., et al. (2021). Inflammatory and prothrombotic biomarkers
- 718 associated with the severity of COVID-19 infection. Clin. Appl. Thromb. Hemost. 27, 1-9.
- 719 doi: 10.1177/1076029621999099

- ⁷²⁰Luo, D., Wan, X., Liu, J., and Tong, T. (2018). Optimally estimating the sample mean from
- 721 the sample size, median, mid-range, and/or mid-quartile range. Stat. Meth. Med. Res. 27,
- ⁷²²1785–1805. doi: 10.1177/0962280216669183
- 723 Luo, L., Xu, M., Du, M., Kou, H., Liao, D., Cheng, Z., et al. (2020). Early coagulation tests
- 724 predict risk stratification and prognosis of COVID-19. Aging (Albany NY). 12, 15918-
- 725 15937. doi: 10.18632/aging.103581
- ⁷²⁶Mikami, T., Miyashita, H., Yamada, T., Harrington, M., Steinberg, D., Dunn, A., and Siau, E.
- ⁷²⁷(2021). Risk factors for mortality in patients with COVID-19 in New York City. J. Gen.
- 728 Intern. Med. 36, 17-26. doi: 10.1007/s11606-020-05983-z
- ⁷²⁹Monteil, V., Kwon, H., Prado, P., Hagelkrüys, A., Wimmer, R. A., Stahl, M., et al. (2020).
- 730 Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade
- 731 soluble human ACE2. Cell 181, 905-913. doi: 10.1016/j.cell.2020.04.004
- 732 National Heart, Lung, and Blood Institute. (2019). Study quality assessment tools. 733 https://www. nhlbi. nih. gov/health-topics/study-quality-assessment-tools [Accessed] 734 September 20^{th} , 2021].
- ⁷³⁵Noh, C. S., Kim, W. Y., and Baek, M. S. (2021). Risk factors associated with the need for 736 oxygen therapy in patients with COVID-19. Medicine. 100, e25819. doi: ⁷³⁷10.1097/md.0000000000025819
- ⁷³⁸Nougier, C., Benoit, R., Simon, M., Desmurs-Clavel, H., Marcotte, G., Argaud. L., et al.
- 739 (2020) Hypofibrinolytic state and high thrombin generation may play a major role in SARS-
- ⁷⁴⁰Cov2 associated thrombosis. J. Thromb. Haemost. 18, 2215-2219. doi: 10.1111/jth.15016

- 745 et al. (2020). Hypercoagulability of COVID-19 patients in intensive care unit: a report of
- 746 thromboelastograpgy and other parameters of hemostasis. J. Thromb. Haemost. 18, 1738-
- 747 1742. doi: 10.1111/jth.14850
- ⁷⁴⁸Pavoni, V., Gianesello, L., Pazzi, M., Stera, C., Meconi, T., Frigieri, F.C. (2020) Evaluation

749 of coagulation function by rotation thromboelastometry in critically ill patients with severe

- ⁷⁵⁰COVID-19 pneumonia. J. Thromb. Thrombolysis. 50, 281-286. doi: 10.1007/s11239-020- 751 02130-7
- 752 Piazza, G., Campia, U., Hurwitz, S., Snyder, J. E., Rizzo, S. M., Pfeferman, M. B., et al.

⁷⁵³(2020). Registry of arterial and venous thromboembolic complications in patients with

⁷⁵⁴COVID-19. J. Am. Coll. Cardiol. 76, 2060-2072. doi: 10.1016/j.jacc.2020.08.070

- 755 Pustejovsky, M.A., and Rodgers, J.E. (2019). Testing for funnel plot asymmetry of
- 756 standardized mean differences. Res. Synthesis Meth. 10, 57-71. doi: 10.1002/jrsm.1332
- 757 Qu, R., Ling, Y., Zhang, Y.H.Z., Wei, L.Y., Chen, X., Li, X.M. et al. (2020). Platelet-to
- ⁷⁵⁸lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J. Med.
- 759 Virol. 92, 1533-1541. doi: 10.1002/jmv.25767
- ⁷⁶⁰Ranucci, M., Ballotta, A., Di Dedda, U., Bayshnikova, E., Dei Poli, M., Resta, M., et al.
- ⁷⁶¹(2020). The procoagulant pattern of patients with COVID-19 acute distress syndrome. J.
- 762 Thromb. Haemost. 18, 1747-1751. doi: 10.1111/jth.14854

- ⁷⁶³Rauch, A., Labreuche, J., Lassalle, F., Goutay, J., Caplan, M., Charbonnier, L., et al. (2020).
- ⁷⁶⁴Coagulation biomarkers are independent predictors of increased oxygen requirements in
- 765 COVID-19. J. Thromb. Haemost. 18, 2942-2953. doi: 10.1111/jth.15067
- 766 Shang, W., Dong, J., Ren, Y., Tian, M., Li, W., Hu, J., et al. (2020). The value of clinical
- 767 parameters in predicting the severity of COVID-19. J. Med. Virol. 92, 2188-2192. doi:
- 768 10.1002/jmv.26031
- 769 Spyropoulos, A. C., Levy, J. H., Ageno, W., Connors, J. M., Hunt, B. J., Iba, T., et al. (2020).
- 770 Scientific and standardization committee communication: clinical guidance on the diagnosis,
- 771 prevention and treatment of venous thromboembolism in hospitalized patients with COVID-
- ⁷⁷²19. J. Thromb. Haemost. 18, 1859–1865. doi: 10.1111/jth.14929
- 773 Suleyman, G., Fadel, R. A., Malette, K. M., Hammond, C., Abdulla, H., Entz, A., et al.
- ⁷⁷⁴(2020). Clinical characteristics and morbidity associated with coronavirus disease-2019 in a
- ⁷⁷⁵series of patients in metropolitan Detroit. JAMA Netw. Open. 3, e2012270. doi: 715
- ⁷⁷⁶10.1001/jamanetworkopen.2020.12270
- ⁷⁷⁷Tang, N., Li, D., Wang, X., and Sun, Z. (2020). Abnormal coagulation parameters are
- 778 associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb.
- 779 Haemost. 18, 844-847. doi: 10.1111/jth.14768
- ⁷⁸⁰Thachil, J., Tang, N., Gando, S., Falanga, A., Cattaneo, M., Levi, M., et al. (2020). ISTH
- 781 interim guidance on recognition and management of coagulopathy in COVID-19. J. Thromb.
- 782 Haemost. 18, 1023-1026. doi: 10.1111/jth.14810
- 783 Thoreau, B., Galland, J., Delrue, M., Neuwirth, M., Stepanian, A., Chauvin, A. et al. (2021).
- ⁷⁸⁴D-Dimer levels and neutropils count as predictive and prognostic factors of pulmonary

785 embolism in severe non-ICU COVID-19 patients. Viruses. 13, 758. doi: 725 786 10.3390/v13050758

- 787 Van der Meijden, P.E.J., Heemskerk, J.W.M. (2019) Platelet biology and functions: new
- 788 concepts and clinical perspectives. Nature Rev. Cardiol. 16, 166-179.
- 789 https://doi.org/10.1038/s41569-018-0110-0
- ⁷⁹⁰Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., et
- 791 al. (2020). Endothelial cell infection and endotheliitis in COVID-19. Lancet 395, 1417–1418.
- 792 doi: 10.1016/S0140-6736(20)30937-5
- 793 Veroniki, A. A., Jackson, D., Viechtbauer, W., Bender, R., Bowden, J., Knapp, G., et al.
- ⁷⁹⁴(2016). Methods to estimate the between-study variance and its uncertainty in meta-analysis.
- 795 Res. Synth. Methods. 7, 55–79. doi: 10.1002/jrsm.1164
- ⁷⁹⁶Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al. (2020). Clinical characteristics of
- ⁷⁹⁷138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.
- 798 JAMA. 323, 1061-1069. doi: 10.1001/jama.2020.1585
- ⁷⁹⁹Wan, X., Wang, W., Liu, J., and Tong, T. (2014). Estimating the Sample Mean and Standard
- 800 Deviation from the Sample Size, Median, Range and/or Interquartile range. BMC Med. Res.
- 801 Methodol. 14, 1-13. doi: 10.1186/1471-2288-14-135
- ⁸⁰²Wang, P., Sha, J., Meng, M., Wang, C., Yao, Q., Zhang, Z., et al. (2020). Risk factors for
- 803 severe COVID-19 in middle-aged patients without comorbidities: a multicentre retrospective
- 804 study. J. Transl. Med. 18, 1-12. doi: 10.1186/s12967-020-02655-8
- ⁸⁰⁵Wang, Y., Yao, L., Zhang, J. P., Tang, P. J., Ye, Z. J., Shen, X. H., et al. (2020). Clinical
- 806 characteristics and laboratory indicator analysis of 67 COVID-19 pneumonia patients in
- 807 Suzhou, China. BMC Infect. Dis. 20,747. doi: 10.1186/s12879-020-05468-8

- 808 Welder, D., Jeon-Slaughter, H., Ashraf, B., Choi, S.-H., Chen, W., Ibrahim, I. et al. (2021).
- 809 Immature platelets as a biomarker for disease severity and mortality in COVID-19 patients.
- 810 Br. J. Haem. 194, 530-536. https://doi.org/10.1111/bjh.17656
- 811 White, D., MacDonald, S., Edwards, T., Bridgeman, C., Hayman, M., Sharp, M., et al.
- 812 (2020). Evaluation of COVID-19 coagulopathy: laboratory characterization using thrombin
- 813 generation and nonconventional haemostasis assays. Int. J. Lab. Hematol. 43, 123-130. doi:
- 814 10.1111/ijlh.13329
- ⁸¹⁵Wong, R.S., Wu, A., To, K.F., Lee, N, Lam, C.W., Wong, C.K., et al. (2003).
- 816 Haematological manifestations in patients with severe acute respiratory syndrome:
- 817 retrospective analysis. Br. Med. J. 326, 1358– 62.
- 818 World Health Organization. (2013). Guidelines for investigation of cases of human infection
- 819 with Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
- 820 (https://cdn.who.int/media/docs/default-source/documents/emergencies/health-topics---
- 821 mers/mers_cov_investigation_guideline_jul132d7b61a0-a593-4527-8246-
- ⁸²²25152b965baf.pdf?sfvrsn=3e2f6c65_1&download=true [Accessed September 30, 2021]
- ⁸²³Wright, F.L., Vogler, T.O., Moore, E.E., Moore, H.B., Wohlauer, M.V., Urban, S., et al.
- ⁸²⁴(2020). Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19
- 825 infection. J. Amer. Col. Surgeons. 231, 193-203. doi: 10.1016/j.jamcollsurg.2020.05.007
- 826 Xiong, M., Liang, X., and Wei Y.D. (2020). Changes in blood coagulation in patients with
- 827 severe coronavirus disease 2019 (COVID-2019): a meta-analysis. Br. J. Haem. 189, 1050-
- 828 1052. doi: 10.1111/bjh.16725
- 829 Yang, M., Ng, M. H., and Li, C. K. (2005). Thrombocytopenia in patients with severe acute
- 830 respiratory syndrome. Hematology 10, 101–105. doi: 10.1080/10245330400026170

- ⁸³¹Yang, X., Yang, Q., Wang, Y., Wu, Y., Xu, J., Yu, Y., et al. (2020). Thrombocytopenia and
- 832 its association with mortality in patients with COVID-19. J. Thromb. Haemost. 18, 1469–72. ⁸³³doi: 10.1111/jth.14848
- 834 Yasuhara, J., Kuno, T., Takagi, H., and Sumitomo, N. (2020). Clinical characteristics of
- ⁸³⁵COVID 19 in children: a systematic review. Pediatr. Pulmonol. 55, 2565-2575. doi: 836 10.1002/ppul.24991
- 837 Yatim, N., Boussier, J., Chocron, R., Hadjadj, J., Philippe, A., Gendron, N. (2021). Platelet

838 activation in critically ill COVID-19 patients. Ann. Intensive Care 11, 113. ⁸³⁹doi.org/10.1186/s13613-021-00899-1

- 840 Young, B. E., Ong, S. W. X., Kalimuddin, S., Low, J. G., Tan, S. Y., Loh, J., et al. (2020).
- ⁸⁴¹Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in

842 Singapore. JAMA 323, 1488-1494. doi: 10.1001/jama.2020.3204

- ⁸⁴³Yu, C., Lei, Q., Li, W., Wang, X., Li, W., and Liu, W. (2020). Epidemiological and clinical 844 characteristics of 1663 hospitalized patients infected with COVID-19 in Wuhan, China: a 845 single-center experience. J. Infect. Public Health. 13, 1202–1209. doi: 846 10.1016/j.jiph.2020.07.002
- 847 Yue, T., Zhou, W., He, J., Wang, H., Liu, Y., Wang, B., et al. (2021). Combined clinical and
- 848 imaging features better predict the critical outcomes of patients with SARS-COV-2. Medicine
- 849 100, e25083. doi: 10.1097/md.0000000000025083
- ⁸⁵⁰Zhang, A., Leng, Y., Zhang, Y., Wu, K., Ji, Y., Lei, S., et al. (2020). Meta-analysis of
- 851 coagulation parameters associated with disease severity and poor prognosis of COVID-19.
- 852 Inter. J. Infect. Dis. 100, 441-448. doi: 10.1016/j.ijid.2020.09.021

- 853 Zhang, H., Wang, X., Fu, Z., Luo, M., Zhang, Z., Zhang, K., et al. (2020). Potential factors
- 854 for prediction of disease severity of COVID-19 patients. medRxiv [Preprint]. doi: ⁸⁵⁵10.1101/2020.03.20.20039818
- 856 Zhang, J., Huang, X., Ding, D., and Tao, Z. (2021). Platelet-driven coagulopathy in COVID-
- 857 19 patients: in comparison to seasonal influenza cases. Exp. Hematol. Oncol. 10, 1-13. doi:
- ⁸⁵⁸10.1186/s40164-021-00228-z
- 859 Zhao, J., Zhu, M., Su, X., Huang, M., Yang, Y., Huang, J., et al. (2021). Clinical features and
- 860 risk factors for severe-critically ill COVID-19 adult patients in Jiangsu, China. Medicine.
- 861 100, e24332. doi: 10.1097/md.0000000000024332
- 862 Zhao, Y., Yu, C., Ni, W., Shen, H., Qiu, M., and Zhao, Y. (2021). Peripheral blood
- ⁸⁶³inflammatory markers in predicting prognosis in patients with COVID-19. Some differences
- 864 with Influenza A. J. Clin. Lab. Anal. 35, e23657. doi: 10.1002/jcla.23657
- ⁸⁶⁵Zheng, X., Chen, J., Deng, L., Fang, Z., Chen, G., Ye, D., et al. (2020). Risk factors for the
- ⁸⁶⁶COVID-19 severity and its correlation with viral shedding: a retrospective cohort study. Int.
- 867 J. Infect. Dis. 93, 952-961. doi: 10.1002/jmv.26367
- 868 Zhou, C., Huang, Z., Tan, W., Li, X., Yin, W., Xiao, Y., et al. (2020). Predictive factors of
- 869 severe coronavirus disease-2019 in previously healthy young adults: a single-center,
- 870 retrospective study. Respir. Res. 21:157, 1-8. doi: 10.1186/s12931-020-01412-1
- 871 Zhu, J., Pang, J., Ji, P., Zhong, Z., Li, H., Li, B. et al. (2020) Coagulation disfunction is
- 872 associated with a severity of COVID-19. J. Med. Virol. 93, 962-972. doi: $10.1002/$ jmv.26336
- 873 Zwetsloot, P.-P., Naald, M.V.D., Sena, E.S., Howells, W.D., IntHout, J., De Groot, J.A.H. et
- 874 al. (2017). Standardized means differences cause funnel plots distortion in publication bias
- 875 assessments. eLife 6, e24260 DOI: 10.7554/eLife.24260

⁸⁷⁶**Legends to the Tables**

- ⁸⁷⁷**Table 1.** Summary of the effect sizes for all coagulation parameters
- ⁸⁷⁸**Table 2.** Summary results of the sensitivity analysis
- ⁸⁷⁹**Table 3.** Summary results of the subgroup analysis
- ⁸⁸⁰**Table 4.** Egger's test for publication bias

⁸⁸³**Legends to the Figures**

⁸⁸⁴**Figure 1.** Flow diagram illustrating the process of data collection

⁸⁸⁵**Figure 2.** Diagram depicting characteristics of selected studies: (**A**) number of publications

886 per country; (**B**) number of patients per country; (**C**) number of publications per severity

887 assessment criterion. The latter (C) indicates the total number of research articles to be 42

888 instead of 41 because one study reported two populations of patients admitted to the hospital

889 at different periods.

890 **Figure 3.** Forest plot of association between COVID-19 severity and (**A)** platelets; (**B)** D-891 dimers.

⁸⁹²**Figure 4.** Forest plots of the association between COVID-19 severity and (**A)** fibrinogen; (**B)**

893 activated partial thromboplastin time; (C) prothrombin time.

894 **Figure 5.** GOSH diagnostic for influential cases in meta-analysis models (**A)** PLT; (**B)** D-895 dimers.

⁸⁹⁶**Figure 6.** GOSH plots fixed for influential studies in meta-analysis models (**A-B)** - 897 fibrinogen; **(C-E)** - APTT, **(F-I)** - prothrombin time.

- ⁸⁹⁸**Figure 7.** Contour-enhanced funnel plots evaluating the presence of publication bias in the
- 899 pool of articles that report association between COVID-19 severity and (**A)** platelets; (**B)** D-
- 900 dimers; (C) fibrinogen; (D) activated partial thromboplastin time; (E) prothrombin time.

⁹⁰³**Legends to Supplementary Materials**

- ⁹⁰⁴**Supplementary File 1.** Criteria for clinical severity of COVID-19 used by the National
- 905 Research Center for Cardiac Surgery.
- ⁹⁰⁶**Supplementary Table 1.** Results of the NIH Quality Assessment.
- ⁹⁰⁷**Supplementary Table 2.** Results of the Egger's test with Pustejovsky's corrected standard 908 error.
- ⁹⁰⁹**Supplementary Figure 1.** Exploring influential cases in meta-analysis models with Baujat
- 910 plots: (A) Platelets, (B) D-dimers, (C) Fibrinogen, (D) Activated partial thromboplastin time,
- 911 (E) Prothrombin time.
- ⁹¹²**Supplementary Figure 2.** Influence diagnostic of meta-analysis model for the association of
- 913 platelets count and COVID-19 severity.
- ⁹¹⁴**Supplementary Figure 3.** Influence diagnostic of meta-analysis model for the association of
- 915 D-dimers concentration and COVID-19 severity.

⁹¹⁶**Supplementary Figure 4.** Influence diagnostic of meta-analysis model for the association of

917 fibrinogen and COVID-19 severity.

⁹¹⁸**Supplementary Figure 5.** Influence diagnostic of meta-analysis model for the association of

- 919 activated partial thromboplastin time and COVID-19 severity.
- ⁹²⁰**Supplementary Figure 6.** Influence diagnostic of meta-analysis model for the association of
- 921 prothrombin time and COVID-19 severity.
- 922 **Supplementary Figure 7.** Search for influential cases by leave-one-out method in meta-

923 analysis models for the association of (A) platelets count, (B) D-dimers and COVID-19

924 severity.

- 925 **Supplementary Figure 8.** Search for influential cases by leave-one-out method in meta-
- 926 analysis models for the association of (A) fibrinogen, (B) APTT and COVID-19 severity.

927 **Supplementary Figure 9.** Search for influential cases by leave-one-out method in meta-

928 analysis model for the association of prothrombin time and COVID-19 severity.

⁹²⁹**Supplementary Figure 10.** Forest plots of association of COVID-19 severity and (A) 930 platelets count and (B) D-dimers with outliers removed.

⁹³¹**Supplementary Figure 11.** Forest plots of association of COVID-19 severity and (A)

932 fibrinogen, (B) activated partial thromboplastin time, and (C) prothrombin time with outliers 933 removed.

⁹³⁴**Supplementary Figure 12.** Exploring the influence of meta-analysis study composition on 935 heterogeneity and pooled effect size: (A) fibrinogen, (B) activated partial thromboplastin 936 $time$, and (C) prothrombin time.

⁹³⁷**Supplementary Figure 13.** Results of three clustering methods (A) K-means, (B) DBSCAN, 938 and (C) Gaussian Mixture on the meta-analysis model for association of fibrinogen and 939 COVID-19 severity.

- ⁹⁴⁰**Supplementary Figure 14.** Results of three clustering methods (A) K-means, (B) DBSCAN,
- 941 and (C) Gaussian Mixture on the meta-analysis model for association of activated partial
- 942 thromboplastin time and COVID-19 severity.
- ⁹⁴³**Supplementary Figure 15.** Results of three clustering methods (A) K-means, (B) DBSCAN,
- 944 and (C) Gaussian Mixture on the meta-analysis model for association of prothrombin time
- 945 and COVID-19 severity.
- ⁹⁴⁶**Supplementary Figure 16.** Exploring presence of publication bias with corrected funnel
- 947 plots: SMD plotted against sample size-based precision estimate: (A) platelets, (B) D-dimers,
- 948 (C) fibrinogen, (D) activated partial thromboplastin time, (E) prothrombin time.